Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.com

StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a report released on Sunday. The firm issued a sell rating on the stock.

Several other brokerages have also recently weighed in on MBRX. Maxim Group decreased their price target on shares of Moleculin Biotech from $45.00 to $20.00 and set a buy rating for the company in a research note on Tuesday, March 26th. Roth Mkm reaffirmed a buy rating and issued a $40.00 target price on shares of Moleculin Biotech in a research report on Friday, April 12th.

Moleculin Biotech Stock Up 1.7 %

Shares of NASDAQ MBRX opened at $3.63 on Friday. The company has a fifty day moving average price of $4.47 and a 200 day moving average price of $6.81. Moleculin Biotech has a 1-year low of $3.35 and a 1-year high of $15.75.

Moleculin Biotech (NASDAQ:MBRX) last posted its quarterly earnings data on Friday, May 10th. The company reported ($2.02) earnings per share for the quarter, topping the consensus estimate of ($3.59) by $1.57. As a group, sell-side analysts forecast that Moleculin Biotech will post -8.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Moleculin Biotech stock. Atticus Wealth Management LLC bought a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 50,001 shares of the company’s stock, valued at approximately $43,000. Atticus Wealth Management LLC owned approximately 0.17% of Moleculin Biotech at the end of the most recent quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.